title: Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis.
abstract: BACKGROUND
  The aim of this study was to compare the clinical features and proliferating cell nuclear antigen (PCNA), p53, Bcl-X, and Bax expression in primary oral basaloid squamous cell carcinoma (BSCC) and poorly differentiated squamous cell carcinoma (PDSCC) matched by stage and site and to assess the possible prognostic significance of these variables.
  
  
  METHODS
  Seventeen cases of oral BSCC were compared with 27 PDSCCs matched by stage and tumor site. In addition, PCNA, p53, Bax, and Bcl-X expression in both carcinomas were evaluated in relation to their clinicopathologic features and prognostic values using the Kaplan-Meier method and Cox regression models.
  
  
  RESULTS
  No statistically significant differences were found between the groups (BSCC and PDSCC) in regard to clinical features and immunohistochemical reactivity for antibodies PCNA, p53, and Bcl-X. In comparison with PDSCC, the BSCC group exhibited a higher Bax score (p = .031). The 5-year and 10-year overall survival, cancer-specific survival, and disease-free survival rates demonstrated no significant differences between the BSCC and PDSCC groups, and the PCNA, p53, Bax, and Bcl-X also showed no prognostic value.
  
  
  CONCLUSIONS
  These results suggest that the clinical and biologic course of BSCC is similar to PDSCC in the oral cavity when clinical stage and site are matched.
authors.affiliation: Faculdade de Odontologia de Bauru, Area de Patologia, Alameda Octávio Pinheiro Brisolla, 9-75 CEP 17012-901, Bauru, São Paulo, Brazil.
authors.forename: Fernanda C G
authors.initials: FC
authors.lastname: Sampaio-Góes
authors.forename: Denise T
authors.initials: DT
authors.lastname: Oliveira
authors.forename: Regina G
authors.initials: RG
authors.lastname: Dorta
authors.forename: Suely
authors.initials: S
authors.lastname: Nonogaki
authors.forename: Gilles
authors.initials: G
authors.lastname: Landman
authors.forename: Inês N
authors.initials: IN
authors.lastname: Nishimoto
authors.forename: Luiz P
authors.initials: LP
authors.lastname: Kowalski
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D009367:Neoplasm Staging; D018307:Neoplasms, Squamous Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis* / Q000235:genetics; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D051028:bcl-2-Associated X Protein / Q000032:analysis* / Q000235:genetics; D051020:bcl-X Protein / Q000032:analysis* / Q000235:genetics
chemical_list: C494826:BAX protein, human; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein